Who are Concerta EG formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROAMPHETAMINE, Tramadol HCl/acetaminophen Extended Release, SPN-812 (600mg, QD), Oral Methamphetamine, Tramadol IV (Tradonal® IV), Paracetamol-Tramadol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/concerta-eg-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Concerta EG formulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Concerta EG formulation (Concerta EG formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central Nervous System Stimulant. Area: Neurology.

phase 2 Central Nervous System Stimulant Norepinephrine transporter Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Concerta EG formulation (Concerta EG formulation) — Janssen Research & Development, LLC. Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Concerta EG formulation TARGET	Concerta EG formulation	Janssen Research & Development, LLC	phase 2	Central Nervous System Stimulant	Norepinephrine transporter
DEXTROAMPHETAMINE	DEXTROAMPHETAMINE		marketed	Central nervous system stimulant	Dopamine transporter (DAT), Norepinephrine transporter (NET)	1955-01-01
Tramadol HCl/acetaminophen Extended Release	Tramadol HCl/acetaminophen Extended Release	Janssen Korea, Ltd., Korea	marketed	Opioid analgesic combination with NSAID alternative	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
SPN-812 (600mg, QD)	SPN-812 (600mg, QD)	Supernus Pharmaceuticals, Inc.	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
Oral Methamphetamine	Oral Methamphetamine	University of California, San Francisco	marketed	Sympathomimetic amine; central nervous system stimulant	Dopamine transporter (DAT), norepinephrine transporter (NET), serotonin transporter (SERT)
Tramadol IV (Tradonal® IV)	Tramadol IV (Tradonal® IV)	University Hospital, Ghent	marketed	Opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Paracetamol-Tramadol	Paracetamol-Tramadol	Astes	marketed	Analgesic combination (non-opioid + opioid)	Cyclooxygenase (COX), opioid receptors (μ, δ, κ), norepinephrine transporter, serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-24 — DEXTROAMPHETAMINE · 9456993 · Formulation · US
2033-10-24 — DEXTROAMPHETAMINE · 9474722 · Formulation · US
2042-01-06 — DEXTROAMPHETAMINE · 11559501 · Formulation · US

Sponsor landscape (Central Nervous System Stimulant class)

Janssen Research & Development, LLC · 2 drugs in this class
Azurity · 1 drug in this class
Novartis · 1 drug in this class
Takeda · 1 drug in this class
UCB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Concerta EG formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/concerta-eg-formulation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing